Literature DB >> 30411817

Predictors of mortality and outcomes in transvenous lead extraction for systemic and local infection cohorts.

Justin Gould1,2, Magdalena Klis1, Bradley Porter1,2, Baldeep S Sidhu1,2, Benjamin J Sieniewicz1,2, Steven E Williams1,2, Thomas Teall1,2, Jessica Webb1,2, Anoop Shetty1, Jaswinder Gill1,2, Christopher A Rinaldi1,2.   

Abstract

BACKGROUND: Transvenous lead extraction (TLE) may be necessary due to infective and noninfective indications. We aim to identify predictors of 30-day mortality and risk factors between infective versus noninfective groups and systemic versus local infection subgroups.
METHODS: A total of 925 TLEs between October 2000 and December 2016 were prospectively collected and dichotomized (infective group n = 505 vs noninfective group n = 420 and systemic infection n = 164 vs local infection n = 341).
RESULTS: All-cause major complication including deaths was significantly higher (5.1%, n = 26 vs 1.2%, n = 5, P = 0.001) as well as 30-day mortality (4.0%, n = 20 vs 0.2%, n = 1, P < 0.001) in the infective group compared to the noninfective group. Both subgroups (systemic vs local infection) were balanced for demographics. All-cause major complication including deaths was significantly higher (9.1%, n = 15 vs 3.2%, n = 11, P = 0.008) as well as all-cause 30-day mortality (7.9%, n  = 13 vs 2.1%, n = 7, P = 0.003) in the systemic infection subgroup compared to the local infection subgroup.
CONCLUSION: Patients undergoing TLE for infective indications are at greater risk of 30-day all-cause mortality compared to noninfective patients. Patients undergoing TLE for systemic infective indications are at greater risk of 30-day all-cause mortality compared to patients with local infection. Renal impairment, systemic infection, and elevated preprocedure C-reactive protein are independent predictors of 30-day all-cause mortality in patients undergoing TLE for an infective indication.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac implantable electronic device infection; device complications; local versus systemic infection; systemic versus local infection; transvenous lead extraction

Mesh:

Year:  2018        PMID: 30411817     DOI: 10.1111/pace.13542

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

1.  Effectiveness and Safety of Transvenous Removal of Cardiac Pacing and Implantable Cardioverter-defibrillator Leads in the Real Clinical Scenario.

Authors:  Roberto Costa; Katia Regina da Silva; Elizabeth Sartori Crevelari; Wagner Tadeu Jurevicius Nascimento; Marcia Mitie Nagumo; Martino Martinelli Filho; Fabio Biscegli Jatene
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

2.  Financial and resource costs of transvenous lead extraction in a high-volume lead extraction centre.

Authors:  Justin Gould; Baldeep S Sidhu; Bradley Porter; Benjamin J Sieniewicz; Scott Freeman; Evelien Cj de Wilt; Julia C Glover; Reza Razavi; Christopher A Rinaldi
Journal:  Heart       Date:  2020-01-13       Impact factor: 5.994

3.  Assessing long-term survival and hospitalization following transvenous lead extraction in patients with cardiac resynchronization therapy devices: A propensity score-matched analysis.

Authors:  Vishal S Mehta; Hugh O'Brien; Mark K Elliott; Baldeep S Sidhu; Justin Gould; Anoop K Shetty; Steven Niederer; Christopher A Rinaldi
Journal:  Heart Rhythm O2       Date:  2021-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.